CU Anschutz In The News

In April of this year, Dr. Jacob Langston, chief resident PGY-5 in the department of radiation oncology at the University of Colorado Anschutz Medical Campus Aurora, and his colleagues published results from a study in the journal Lung Cancer, in which 12 patients with non-small cell lung cancer (NSCLC) were treated with tyrosine kinase inhibitors first before they proceeded to stereotactic radiotherapy.

“I do believe things are looking really good for patients with DLBCL,” Dr. Manali Kamdar, a clinical researcher in the field of blood cancers at the University of Colorado Anschutz Medical Campus, tells us. Kamdar describes 2022 and 2023 as “pivotal in terms of having more medications approved for patients with large-cell lymphoma.”